End Price Gouging for Medications Act
Sponsor
Full profile: /officials/D000624
Source: Congress.gov · FEC
Cosponsors (1)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
1 cosponsor on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Currently in
- House Committee on Natural ResourcesReferred To · 2025-05-14
- House Committee on Oversight and Government ReformReferred To · 2025-05-14
- House Committee on Armed ServicesReferred To · 2025-05-14
- House Committee on Ways and MeansReferred To · 2025-05-14
- House Committee on Energy and CommerceReferred To · 2025-05-14
- House Committee on Veterans' AffairsReferred To · 2025-05-14
Plain-English Summary
The legislation would allow the federal government to investigate and penalize pharmaceutical companies that dramatically raise prices on existing medications without justification. It would give regulators tools to cap prices on drugs when they determine companies are unfairly exploiting patients and insurance companies, particularly for life-saving or essential medications. The law would affect drug manufacturers, patients paying for prescriptions, and insurance companies that cover medication costs.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- HRES1437Recognizing that equity, diversity, and inclusion in federally funded health research is necessary to enhance scientific excellence, and ensure equitable outcomes for patients in the United States.Referred to Committee · 2026-07-16
- HR9703Improving Access to Transfusion Care for Hospice Patients Act of 2026Referred to Committee · 2026-07-15
- HR9671To expand access for workers experiencing symptoms related to menopause and the menopause transition to reasonable accommodations that enable them to perform the essential functions of their job without risking their health or economic security.Referred to Committee · 2026-07-14
- HR9594No PFAS in Cosmetics ActReferred to Committee · 2026-07-06